Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Stilgenbauer, S; Zenz, T; Winkler, D; Bühler, A; Schlenk, RF; Groner, S; Busch, R; Hensel, M; Dührsen, U; Finke, J; Dreger, P; Jäger, U; Lengfelder, E; Hohloch, K; Söling, U; Schlag, R; Kneba, M; Hallek, M; Döhner, H; German Chronic Lymphocytic Leukemia Study Group 
Titel:
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. 
Abstract:
PURPOSE: The phase II CLL2H trial evaluated safety and efficacy of subcutaneous alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). Clinical and biologic markers were evaluated for their impacts on outcome. PATIENTS AND METHODS: One hundred nine patients were enrolled, and 103 received at least one dose of alemtuzumab. After dose escalation, alemtuzumab was administered subcutaneously at 30 mg three times weekly for up to 12 weeks. Response was assessed every...    »
 
Zeitschriftentitel:
J Clin Oncol 
Jahr:
2009 
Band / Volume:
27 
Heft / Issue:
24 
Seitenangaben Beitrag:
3994-4001 
Sprache:
eng 
Print-ISSN:
0732-183X 
TUM Einrichtung:
r Medizinische Statistik und Epidemiologie